Cassava Sciences' stock is highly shorted, with potential reward tied to the upcoming Phase 3 trial results for simufilam.

Those who took the drug survived a median two extra months (22.6 vs 20.2 months ... Weiss disclosed advisory board (Alexion, Ra [now UCB], argenx, Biogen, Mitsubishi Tanabe Pharma, Amylyx ...

which prompted Merck to add extra patients outside these countries. It also amended the trial protocol to be event-driven. Meanwhile, Roche''s fenebrutinib and Biogen's orelabrutinib are two other ...

Deep-pocketed investors have adopted a bearish approach towards Biogen (NASDAQ:BIIB), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga ...

Biogen Inc.'s stock rose 1% Thursday, after Europe's pharmaceutical regulator issued a positive opinion on the Alzheimer's disease drug that the company developed with Japanese partner Eisai ...

Nov 14 (Reuters) - The European Union's drugs regulator on Thursday recommended approval of Eisai (4523.T), opens new tab and Biogen's (BIIB.O), opens new tab Leqembi for some patients with early ...

A stock is considered to be oversold if the RSI reading falls below 30. In trading on Monday, shares of Biogen Inc (Symbol: BIIB) entered into oversold territory, hitting an RSI reading of 29.8 ...

Upon reexamination, the European Medicines Agency has made a U-turn on Eisai and Biogen’s Alzheimer’s disease drug Leqembi. After a rejection in July, drug reviewers at the EMA have now ...

In this article, we are going to take a look at where Biogen Inc. (NASDAQ:BIIB) stands against the other oversold large cap stocks. The Fed recently reduced the funds rate by 50 basis points ...

We think Biogen's neurology, immunology, and focus on rare diseases support a narrow moat. Biogen's strategy has its roots in the 2003 merger of Biogen (Avonex for treating multiple sclerosis ...

Biogen (BIIB) announced a research collaboration to discover and develop molecular glue degraders for priority targets in Alzheimer’s, rare neurological, and immunological diseases. As part of ...

Biogen is making a few changes to its C-suite. The drugmaker will bring on Bristol Myers Squibb exec Daniel Quirk as chief medical officer and head of medical affairs, a move announced one day after ...